Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
NCT ID: NCT00467506
Last Updated: 2011-11-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2004-05-31
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bispecific antibody and di-DTPA-131I
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Karnofsky ≥ 70%
* Histological diagnosis of medullary thyroid carcinoma
* Calcitonin serum level Ê 100 pg/ml and Calcitonin or CEA doubling time £ 5 years
* Normal liver and renal functions
* Granulocytes ≥ 1500/mm3 and platelets ≥ 150 000/mm3
* No immunization
* Consent form signed
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francoise Bodere, MD
Role: PRINCIPAL_INVESTIGATOR
Nantes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre François Baclesse
Caen, , France
CHU de Grenoble
Grenoble, , France
hôpital du Cluzeau
Limoges, , France
CHU
Lyon, , France
Hôpital de la timone
Marseille, , France
CHU
Nantes, , France
CHU
Rouen, , France
Centre René Huguenin
Saint-Cloud, , France
Centre René Gauducheau
Saint-Herblain, , France
Centre Paul Strauss
Strasbourg, , France
Centre Claudius Régaud
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRD 03/2-U
Identifier Type: -
Identifier Source: org_study_id